Disturbed clinical trials due to conflicts in the DRC has forced scientists to change the way of immunizing people. More than 500 participants enrolled from the Democratic Republic of the Congo. For an innovative study of experimental drugs as a response to the ongoing outbreak in the area. An ongoing outbreak in DRC is the first to strike in a war situation and second-largest on record. The current situation in DRC prompted the World Health Organization (WHO) to announce a public health emergency of international concern on 17 July. According to the agency, approximately 2,600 people have been infected with Ebola, and more than 1,700 people have died in DRC.
The ongoing breakdown has forced researchers to adapt and endure to an extraordinary degree. They have adopted new methods of conducting rigorous studies in areas of war and where Ebola responders have been attacked repeatedly. Muyembe, a scientist working on ebola since 1976 and other researchers have developed a blueprint for a randomized clinical trial comprising of four drugs, which ensures one of the four treatments for patients who participate. The innovative design of the clinical trial lets the trial to stop and start as needed. This flexibility has proven vital among the ever-present violence where Ebola is spreading.
To adapt to the violence and conflict, clinical researchers at a French medical charity ALIMA operated Ebola center in Benin. This gives mobile phones to patients who check out of the clinic for emergencies and staying updated about lingering symptoms. During, 2014-16 breakdown, researchers at INRB were struggling to send blood samples outside the DRC. But the DRC government rejected it. In the end, blood sample-based scientific papers and patents were authored by scientists at institutions in the United States and Europe. This discouraged researcher in the countries shrunken by the virus. Who had hoped that their study would help to answer back to future infectious-disease outbreaks?